(Z)-1-bromo-11-tetradecene | 76599-56-9

• 分子结构分类: 有机化合物 - 有机卤素化合物 - 有机溴化物
• 英文名称: (Z)-1-bromo-11-tetradecene
• 英文别名: Z-11-tetradecenyl bromide；(Z)-14-bromo-3-tetradecene；(Z)-1-Bromo-11-tetradecene；(Z)-14-bromotetradec-3-ene
• CAS: 76599-56-9
• 化学式: C₁₄H₂₇Br
• 分子量: 275.272
• InChiKey: SYAFMCQKFHDZMO-ARJAWSKDSA-N

物化性质

• 沸点：
  307.9±11.0 °C(Predicted)
• 密度：
  1.033±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  15
• 可旋转键数：
  11
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  (Z)-1-bromo-11-tetradecene 在 sodium hexamethyldisilazane 作用下， 以 四氢呋喃 、 乙腈 为溶剂， 生成
  参考文献：
  名称：

  Synthesis of long-chain fatty acid derivatives as a novel anti-Alzheimer’s agent

  摘要：

  In order to develop new drugs for Alzheimer's disease, we prepared 17 fatty acid derivatives with different chain lengths and different numbers and positions of double bonds by using Wittig reaction and stereospecific hydrogenation of triple bonds as key reactions. Among them, (4Z,15Z)-octadecadienoic acid (10) and (23Z,34Z)-heptatriacontadienoic acid (16) showed the most potent neurite outgrowth activities on A beta(25-35)-treated rat cortical neurons, which activities were comparable to that of a positive control, NGF. Both fatty acids 10 and 16 possess two (Z)-double bonds at the n-3 and n-14 positions, which might be important for the neurite outgrowth activity. (C) 2013 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2013.12.008
• 作为产物：
  描述：

  顺-11-十四碳烯-1-醇 在 三乙胺 、 lithium bromide 作用下， 以 二氯甲烷 、 丙酮 为溶剂， 反应 4.5h， 生成 (Z)-1-bromo-11-tetradecene
  参考文献：
  名称：

  用于体外 DNA 递送的可生物降解吡啶鎓两亲物的合成及特性

  摘要：

  吡啶鎓两亲物已发现将 DNA 输送到真核细胞中的实际应用。已经设计了一种从（异）烟酰氯开始的通用合成方法，用于制备基于（生物）可降解酯的吡啶鎓两亲物，允许疏水部分和头部区域的结构变化。通过差示扫描量热法、透射电子显微镜和紫外线测量，已经确定了一些特性，包括水解行为。已使用真核 COS-7 细胞系测定了体外转染能力和毒性。

  DOI：

  10.1002/1099-0690(200204)2002:7<1271::aid-ejoc1271>3.0.co;2-g

文献信息

• Process for preparing functional group-containing olefinic compounds
  申请人：Wicki Markus A.

  公开号：US06838576B1

  公开（公告）日：2005-01-04

  A process for preparing functional group-containing olefinic compounds comprises the steps of (a) reacting at least one alkylidene phosphorane with at least one carbonyl-containing compound that comprises at least one group that is a leaving group, or that is capable of subsequent conversion to a leaving group, to form an olefinic compound that comprises at least one leaving group, the carbonyl-containing compound being selected from the group consisting of ketones and aldehydes; and (b) reacting the olefinic compound with at least one functional group-containing nucleophile to form a functional group-containing olefinic compound.

  制备含官能团的烯烃化合物的方法包括以下步骤：(a)将至少一种烯烃膦烷与至少一种含有至少一个离去基团的羰基化合物反应，或者能够随后转化为离去基团，形成含有至少一个离去基团的烯烃化合物，所述羰基化合物选自酮和醛的群组；以及(b)将所述烯烃化合物与至少一种含官能团的亲核试剂反应，形成含官能团的烯烃化合物。
• Acetylenic alpha -amino acid-based sulfonamide hydroxamic acid tace inhibitors
  申请人：——

  公开号：US20030008849A1

  公开（公告）日：2003-01-09

  Compounds of the formula: 1 are useful in treating disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

  公式为1的化合物可用于治疗由TNF-&agr;介导的疾病条件，例如类风湿性关节炎、骨关节炎、败血症、艾滋病、溃疡性结肠炎、多发性硬化症、克罗恩病和退行性软骨丢失。
• Acetylenic alpha-amino acid-based sulfonamide hydroxamic acid tace inhibitors
  申请人：Levin I. Jeremy

  公开号：US20050113346A1

  公开（公告）日：2005-05-26

  Compounds of the formula: are useful in treating disease conditions mediated by TNF-α, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

  式为的化合物在治疗由TNF-α介导的疾病条件方面非常有用，例如类风湿性关节炎、骨关节炎、败血症、艾滋病、溃疡性结肠炎、多发性硬化症、克罗恩病和退行性软骨损失。
• Acetylenic &agr;-amino acid-based sulfonamide hydroxamic acid tace inhibitors
  申请人：American Cyanamid Company

  公开号：US06225311B1

  公开（公告）日：2001-05-01

  Compounds of the formula: are useful in treating disease conditions mediated by TNF-&agr;, such as rheumatoid arthritis, osteoarthritis, sepsis, AIDS, ulcerative colitis, multiple sclerosis, Crohn's disease and degenerative cartilage loss.

  分子式为的化合物在治疗由TNF-α介导的疾病条件方面非常有用，例如类风湿性关节炎，骨关节炎，败血症，艾滋病，溃疡性结肠炎，多发性硬化症，克罗恩病和退行性软骨丢失。
• ACETYLENIC ALPHA-AMINO ACID-BASED SULFONAMIDE HYDROXAMIC ACID TACE INHIBITORS
  申请人：Wyeth Holdings Corporation

  公开号：EP1144368B1

  公开（公告）日：2004-07-14